These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

656 related items for PubMed ID: 8817142

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effects on coagulation and fibrinolysis with reduced versus full systemic heparinization and heparin-coated cardiopulmonary bypass.
    Ovrum E, Brosstad F, Am Holen E, Tangen G, Abdelnoor M.
    Circulation; 1995 Nov 01; 92(9):2579-84. PubMed ID: 7586360
    [Abstract] [Full Text] [Related]

  • 3. Completely heparinized cardiopulmonary bypass and reduced systemic heparin: clinical and hemostatic effects.
    Ovrum E, Holen EA, Tangen G, Brosstad F, Abdelnoor M, Ringdal MA, Oystese R, Istad R.
    Ann Thorac Surg; 1995 Aug 01; 60(2):365-71. PubMed ID: 7646097
    [Abstract] [Full Text] [Related]

  • 4. Surface-bound heparin fails to reduce thrombin formation during clinical cardiopulmonary bypass.
    Gorman RC, Ziats N, Rao AK, Gikakis N, Sun L, Khan MM, Stenach N, Sapatnekar S, Chouhan V, Gorman JH, Niewiarowski S, Colman RW, Anderson JM, Edmunds LH.
    J Thorac Cardiovasc Surg; 1996 Jan 01; 111(1):1-11; discussion 11-2. PubMed ID: 8551753
    [Abstract] [Full Text] [Related]

  • 5. Low dose systemic heparinization combined with heparin-coated extracorporeal circulation. Effects related to platelets.
    Mirow N, Brinkmann T, Minami K, Tenderich G, Schulte-Eistrup S, Kleesiek K, Körfer R.
    J Cardiovasc Surg (Torino); 2001 Oct 01; 42(5):579-85. PubMed ID: 11562580
    [Abstract] [Full Text] [Related]

  • 6. Changes in platelet, granulocyte, and complement activation during cardiopulmonary bypass using heparin-coated equipment.
    Fukutomi M, Kobayashi S, Niwaya K, Hamada Y, Kitamura S.
    Artif Organs; 1996 Jul 01; 20(7):767-76. PubMed ID: 8828766
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Clinical study of platelet function and coagulation/fibrinolysis with Duraflo II heparin coated cardiopulmonary bypass equipment.
    Nakajima T, Osawa S, Ogawa M, Sasaki T, Izumoto H, Yagi Y, Kawazoe K.
    ASAIO J; 1996 Jul 01; 42(4):301-5. PubMed ID: 8828788
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Cardiopulmonary bypass with heparin-coated circuits and reduced systemic anticoagulation.
    Kuitunen AH, Heikkilä LJ, Salmenperä MT.
    Ann Thorac Surg; 1997 Feb 01; 63(2):438-44. PubMed ID: 9033316
    [Abstract] [Full Text] [Related]

  • 12. Heparin-coated cardiopulmonary bypass circuits reduce blood cell trauma. Experiments in the pig.
    Thelin S, Bagge L, Hultman J, Borowiec J, Nilsson L, Thorelius J.
    Eur J Cardiothorac Surg; 1991 Feb 01; 5(9):486-91. PubMed ID: 1931093
    [Abstract] [Full Text] [Related]

  • 13. Comparison of a Duraflo II-coated cardiopulmonary bypass circuit and a trillium-coated oxygenator during open-heart surgery.
    Hoel TN, Videm V, Baksaas ST, Mollnes TE, Brosstad F, Svennevig JL.
    Perfusion; 2004 May 01; 19(3):177-84. PubMed ID: 15298426
    [Abstract] [Full Text] [Related]

  • 14. Heparin-coated extracorporeal circulation with full and low dose heparinization: comparison of thrombin related coagulatory effects.
    Mirow N, Brinkmann T, Minami K, Tenderich G, Kleesiek K, Körfer R.
    Artif Organs; 2001 Jun 01; 25(6):480-5. PubMed ID: 11453879
    [Abstract] [Full Text] [Related]

  • 15. Reducing thrombin formation during cardiopulmonary bypass: is there a benefit of the additional anticoagulant action of aprotinin?
    Dietrich W.
    J Cardiovasc Pharmacol; 1996 Jun 01; 27 Suppl 1():S50-7. PubMed ID: 8938284
    [Abstract] [Full Text] [Related]

  • 16. Clinical and biomaterial evaluation of hyaluronan-based heparin-bonded extracorporeal circuits with reduced versus full systemic anticoagulation in reoperation for coronary revascularization.
    Gunaydin S, Farsak B, McCusker K, Vijay V, Sari T, Onur MA, Gurpinar A, Zorlutuna Y.
    J Cardiovasc Med (Hagerstown); 2009 Feb 01; 10(2):135-42. PubMed ID: 19377380
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Maintenance of blood heparin concentration rather than activated clotting time better preserves the coagulation system in hypothermic cardiopulmonary bypass.
    Shirota K, Watanabe T, Takagi Y, Ohara Y, Usui A, Yasuura K.
    Artif Organs; 2000 Jan 01; 24(1):49-56. PubMed ID: 10677157
    [Abstract] [Full Text] [Related]

  • 19. Comparison of three oxygenator-coated and one total-circuit-coated extracorporeal devices.
    Baksaas ST, Videm V, Pedersen T, Karlsen H, Mollnes TE, Brosstad F, Svennevig JL.
    Perfusion; 1999 Mar 01; 14(2):119-27. PubMed ID: 10338323
    [Abstract] [Full Text] [Related]

  • 20. Perioperative course and recovery after heparin-coated cardiopulmonary bypass: low-dose versus high-dose heparin management.
    Weiss BM, von Segesser LK, Turina MI, Seifert B, Pasch T.
    J Cardiothorac Vasc Anesth; 1996 Jun 01; 10(4):464-70. PubMed ID: 8776638
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.